

Outpatient Medical Injectable Rituximab and Biosimilars Request Form Fax to 833-619-5745 (Medical Benefit Only)

| Member Date of Birth: | | | | | | |
|--|---|--|--|--|--|--|
| Member UMI: | | | | | | |
| Requesting Physician's Name:NPI Number: | | | | | | |
| Requesting Physician's Address: | | | | | | |
| Office Contact: Phone #: | | | | | | |
| Facility NPI Number: | | | | | | |
| Facility's Address: | | | | | | |
| Date of Service: | | | | | | |
| Diagnosis Code(s): | | | | | | |
| DRUG INFORMATION (please select one) | | | | | | |
| PREFERRED PRODUCT FOR RHEUMATOID ARTHRITIS | NON-PREFERRED | | | | | |
| Ruxience (Q5119) | Rituxan (J9312) | | | | | |
| ☐ Riabni (Q5123) | ☐ Truxima (Q5115) | | | | | |
| | Has the member experienced a documented drug therapy failure or intolerance to the preferred products? Ruxience: Yes No Riabni: Yes No *A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial of BOTH preferred products, or BOTH preferred products have not been tolerated or are contraindicated *Medicare members currently established on a | | | | | |
| | Phone #: | | | | | |

^{**}Please verify member's eligibility and benefits through the health plan**

| Please answer the following for ONCOLOGY indications: (for non-oncology indications please proceed to question 6) | | | | | |
|---|---|---|---------------|----------------------------|--|
| 1. | • • | cer does the member have (include nat stage disease? | | | |
| 2. | What is the mem | ber's chemotherapy regimen? | | | |
| 3. | What line of ther Subsequent)? | apy is this considered (First, Second, | | | |
| 4. | • | rerapies has the member received? the patient progressed or relapsed) | | | |
| 5. | Is the patient's di | sease CD20-positive? | □YES | □NO □ NOT APPLICABLE | |
| Please answer the following for a NON-ONCOLOGY indication: (In addition please make sure the accurate icd10 diagnosis code was given above) | | | | | |
| 6. | 5. What medications (if any) has the member previously used for this condition? | | | | |
| 7. | 7. What medications (if any) will the member be using in conjunction for the condition? | | | | |
| 8. | What is the dose treatment? | What is the dose and frequency of the member's treatment? Dose: Frequency: | | | |
| 9. | | d Arthritis indications ONLY s RA moderately to severely active? | | □YES □NO | |
| | New Start | ☐ Continuation of Therapy | | | |
| | | Date of last infusion: | | | |
| | | Has the member demonstrated diseas therapy? ☐ YES ☐ NO | e stability o | r a beneficial response to | |
| | | | | | |
| Please attach all pertinent clinical information Attached: YES NO | | | | | |
| | | | | | |

^{**}Please verify member's eligibility and benefits through the health plan**